Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

with results showing a single infusion of its LAG-3 blocker relatlimab and its Opdivo immunotherapy improved progression-free survival in advanced melanoma compared with the PD-1 class Opdivo alone.

A research team led by Sheri Holmen, Ph.D., investigator at Huntsman Cancer Institute and professor in the Department of ...

Flat dose regimens in two studies (nivolumab 20 mg or 100 mg once every 3 weeks and pembrolizumab 100 mg once every 3 weeks) also demonstrated comparable OS in NSCLC. Limited data suggested that a ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

A federally funded research team led by Sheri Holmen, PhD, investigator at Huntsman Cancer Institute and professor in the ...

Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.